383 305

Cited 0 times in

고지혈증 치료 가이드라인

DC FieldValueLanguage
dc.contributor.author이상학-
dc.date.accessioned2019-12-18T00:27:06Z-
dc.date.available2019-12-18T00:27:06Z-
dc.date.issued2019-
dc.identifier.issn1226-329X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/173051-
dc.description.abstractThe major guidelines for lipid-lowering therapy (LLT) have been revised recently. Although “higher cardiovascular risk-aggressive LLT with greater absolute clinical benefit” is the main idea underlying all guidelines, there are some differences in the details among them. The US guidelines recommend pharmacological LLT based on a patient’s risk category, independently of their low-density lipoprotein-cholesterol (LDL-C) level. However, the European and Korean guidelines consider the patient’s risk category and LDL-C at the same time. Lifestyle modifications are suggested in parallel in all guidelines. The newest US guidelines have characteristically revived target LDL-C values in some patient groups and indications for non-statin drugs (ezetimibe and PCSK9 inhibitors), whereas the European and Korean guidelines have maintained target LDL-C values as usual. It is universally accepted that statins are the first-line agent. Adding ezetimibe, bile acid sequestrants, or PCSK9 inhibitors is recommended as a second line treatment. Appreciating the trend and background of the newest LLT guidelines will be essential to maximize cardiovascular prevention in patients.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageKorean-
dc.publisher대한내과학회-
dc.relation.isPartOfKorean Journal of Medicine-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.title고지혈증 치료 가이드라인-
dc.title.alternativeLipid-Lowering Therapy Guidelines-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthor이상학-
dc.identifier.doi10.3904/kjm.2019.94.5.396-
dc.contributor.localIdA02833-
dc.relation.journalcodeJ02059-
dc.subject.keywordCholesterol-
dc.subject.keywordAtherosclerosis-
dc.subject.keywordTherapeutics-
dc.subject.keywordLipoproteins-
dc.contributor.alternativeNameLee, Snag Hak-
dc.contributor.affiliatedAuthor이상학-
dc.citation.volume94-
dc.citation.number5-
dc.citation.startPage396-
dc.citation.endPage402-
dc.identifier.bibliographicCitationKorean Journal of Medicine, Vol.94(5) : 396-402, 2019-
dc.identifier.rimsid64619-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.